Eli Lilly

Showing 15 posts of 218 posts found.

lilly_corporate_hq

Interim analysis fails to show benefits for Lilly’s abemaciclib in advanced breast cancer

August 10, 2016
Research and Development Eli Lilly, abemaciclib, breast cancer

Eli Lilly has announced that, after a pre-planned interim analysis for their Phase III MONARCH2 trial, investigators have decided to …

johnnolech

John Lechleiter to step down as Lilly CEO

July 27, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, John Lechleiter

Eli Lilly has announced that CEO John Lechleiter is set to retire, with David Ricks to assume the role as …

headquarters_2_web

Eli Lilly Q2 2016 results surpass estimates

July 27, 2016
Research and Development, Sales and Marketing Eli Lilly, financial report

Eli Lilly has released its financial report for the second quarter of 2016, noting a number of promising results.  The …

cancerstudy

Lilly, Boehringer Ingelheim to jointly study combination therapy for breast cancer

July 14, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, breast cancer, combination therapy, drug trial

US drug major Eli Lilly (NYSE: LLY) and Boehringer Ingelheim said they will jointly initiate early combination trials in breast cancer. The …

eli_lilly_logo

Eli Lilly says FDA panel backs approval of Jardiance for cardiovascular indication

June 30, 2016
Research and Development, Sales and Marketing Eli Lilly, cardiovascular, diabetes, jardiance

US drugmaker Eli Lilly (NYSE: LLY) said a US regulatory panel has backed its Jardiance (empagliflozin) for reducing cardiovascular death …

lilly_entrance_web

German Supreme Court grants Lilly appeal to block Alimta generics

June 15, 2016
Research and Development, Sales and Marketing Actavis, Alimta, Eli Lilly

Eli Lilly (NYSE: LLY) has announced that it has been granted an appeal by the German Federal Supreme Court, in …

FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug

June 1, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, diabetes, jentadueto, jentadueto xr, lilly, partnership, type 2, type-2

The US Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release) tablets for the …

eli_lilly_logo

Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance

May 26, 2016
Research and Development, Sales and Marketing Cancer Drugs Fund, Eli Lilly, NICE, lung cancer

The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat …

lilly_entrance_web

Eli Lilly showcases emerging pipeline to investors

May 25, 2016
Research and Development Eli Lilly, investors, lilly, pipeline, research and development

Eli Lilly and Co (NYSE: LLY) has showcased its emerging pipeline to potential investors, highlighting its potential to launch 20 …

Nice recommends three drugs to treat diabetes

May 25, 2016
Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes

The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …

lilly_entrance_web

FDA issues warning about rare, but serious, side effect in Lilly antipsychotic drug

May 12, 2016
Medical Communications, Sales and Marketing Eli Lilly, FDA, anti-psychotic, boxed warning, lilly, olanzapine, skin condition

The US Food and Drug Administration (FDA) has issued a new warning to all drug labels for Eli Lilly’s antipsychotic …

headquarters_3_web

Eli Lilly’s cancer drug candidate scores FDA priority review

May 5, 2016
Eli Lilly, US FDA, oncology, regulation

US drugmaker Eli Lilly (NYSE: LLY) said the US Food and Drug Administration (FDA) has granted priority review for its …

NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis

April 27, 2016
Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation

The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …

headquarters_3_web

Eli Lilly Q1 earnings miss estimates, ups FY view; shares drop 2%

April 27, 2016
Research and Development, Sales and Marketing Eli Lilly, FY, Q1, earnings, revenue, sales

Shares in US drugmaker Eli Lilly (NYSE: LLY) dropped to close down over 2% Tuesday after the company posted first-quarter …

eli_lilly_logo

Eli Lilly gets European marketing authorisation for psoriasis drug

April 26, 2016
EC, EU, Eli Lilly, drug trial, psoriasis, regulation

US pharma firm Eli Lilly and Co (NYSE: LLY) on Tuesday said the European Commission backed marketing authorisation for its …

The Gateway to Local Adoption Series

Latest content